litlas
Log inCreate account

Robert S. Mannel

Active 1994–2025

81
Papers
19,403
Citations
58
h-index
75
i10-index

Citations

Citations per year for Robert S. Mannel1993: 1 citations1994: 2 citations1995: 2 citations1996: 2 citations1997: 1 citations1998: 3 citations1999: 2 citations2000: 2 citations2001: 4 citations2002: 6 citations2003: 13 citations2004: 19 citations2005: 32 citations2006: 60 citations2007: 64 citations2008: 53 citations2009: 77 citations2010: 69 citations2011: 72 citations2012: 107 citations2013: 106 citations2014: 131 citations2015: 104 citations2016: 132 citations2017: 141 citations2018: 136 citations2019: 613 citations2020: 623 citations2021: 553 citations2022: 443 citations2023: 441 citations2024: 749 citations2025: 483 citations2026: 45 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,728 citing papers, 23.4% of this breakdownChina: 807 citing papers, 11% of this breakdownItaly: 476 citing papers, 6.5% of this breakdownUnited Kingdom: 461 citing papers, 6.3% of this breakdownCanada: 325 citing papers, 4.4% of this breakdownFrance: 307 citing papers, 4.2% of this breakdownGermany: 301 citing papers, 4.1% of this breakdownJapan: 261 citing papers, 3.5% of this breakdownSpain: 232 citing papers, 3.1% of this breakdownAustralia: 186 citing papers, 2.5% of this breakdownSouth Korea: 178 citing papers, 2.4% of this breakdownNetherlands: 178 citing papers, 2.4% of this breakdown
0%23.4%Other 26.2%

Institutions

Fields

  • Medicine71.2%
  • Biochemistry, Genetics and Molecular Biology15.6%
  • Computer Science5.7%
  • Immunology and Microbiology2.3%
  • Engineering1.3%
  • Neuroscience1%
  • Other2.9%

Topics

  • Ovarian cancer diagnosis and treatment12.9%
  • Endometrial and Cervical Cancer Treatments10%
  • PARP inhibition in cancer therapy5.3%
  • Intraperitoneal and Appendiceal Malignancies2.5%
  • Uterine Myomas and Treatments2.2%
  • BRCA gene mutations in cancer1.8%
  • Other65.3%

Coauthors

All papers

Open in search
  1. Recent advances and clinical applications of deep learning in medical image analysis

    Authors: Xuxin Chen, Ximin Wang, Ke Zhang, Roy Zhang, Kar-Ming Fung, Theresa C. Thai, Kathleen N. Moore, Robert S. Mannel, Hong Liu, Bin Zheng, Yuchen Qiu - Medical Image Analysis, Medical Image Anal. 2022 cited by 1,010

  2. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

    Authors: Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian - New England Journal of Medicine 2023 cited by 701

  3. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

    Authors: Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang - New England Journal of Medicine 2011 cited by 2,384

  4. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    Authors: Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel - The Lancet Oncology 2017 cited by 602

  5. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

    Authors: David S. Miller, Virginia L. Filiaci, Robert S. Mannel, David E. Cohn, Takashi Matsumoto, Krishnansu S. Tewari, Paul DiSilvestro, Michael L. Pearl, Peter A. Argenta, Matthew A. Powell, Susan Zweizig, David Warshal, Parviz Hanjani, Michael E. Carney, Helen Huang, David Cella, Richard J. Zaino, Gini F. Fleming - Journal of Clinical Oncology 2020 cited by 340

  6. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

    Authors: Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk - Journal of Clinical Oncology 2019 cited by 483

  7. Inherited Mutations in Women With Ovarian Carcinoma

    Authors: Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer - JAMA Oncology 2015 cited by 764

  8. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

    Authors: Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen - Journal of Clinical Oncology 2003 cited by 2,055

  9. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

    Authors: Robert L. Coleman, Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Jae‐Weon Kim, Sang‐Yoon Park, Byoung‐Gie Kim, Joo-Hyun Nam, Keiichi Fujiwara, Joan L. Walker, A.Catherine Casey, Angeles Alvarez Secord, Steve Rubin, John K. Chan, Paul DiSilvestro, Susan A. Davidson, David E. Cohn, Krishnansu S. Tewari, Karen Basen‐Engquist, Helen Huang, Mark F. Brady, Robert S. Mannel - New England Journal of Medicine 2019 cited by 334

  10. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

    Authors: John Farley, William E. Brady, Vinod Vathipadiekal, Heather A. Lankes, Robert L. Coleman, Mark A. Morgan, Robert S. Mannel, S. Diane Yamada, David G. Mutch, William H. Rodgers, Michael J. Birrer, David M. Gershenson - The Lancet Oncology 2012 cited by 413

  11. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

    Authors: Marcus E. Randall, Virginia L. Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M. Yashar, Robert S. Mannel, Jae‐Weon Kim, Ritu Salani, Paul DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Y. Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol Aghajanian, David S. Miller - Journal of Clinical Oncology 2019 cited by 328

  12. Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2

    Authors: Joan L. Walker, Marion Piedmonte, Nick M. Spirtos, Scott M. Eisenkop, John B. Schlaerth, Robert S. Mannel, Gregory Spiegel, Richard R. Barakat, Michael L. Pearl, Sudarshan Sharma - Journal of Clinical Oncology 2009 cited by 1,295

  13. Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study

    Authors: Joan L. Walker, Marion R. Piedmonte, Nick M. Spirtos, Scott M. Eisenkop, John B. Schlaerth, Robert S. Mannel, Richard R. Barakat, Michael L. Pearl, Sudarshan Sharma - Journal of Clinical Oncology 2012 cited by 778

  14. MICU1 drives glycolysis and chemoresistance in ovarian cancer

    Authors: Prabir K. Chakraborty, Soumyajit Banerjee Mustafi, Xunhao Xiong, Shailendra Kumar Dhar Dwivedi, Vasyl Nesin, Sounik Saha, Min Zhang, Danny N. Dhanasekaran, Muralidharan Jayaraman, Robert S. Mannel, Kathleen N. Moore, Scott McMeekin, Da Yang, Rosemary E. Zuna, Kai Ding, Leonidas Tsiokas, Resham Bhattacharya, Priyabrata Mukherjee - Nature Communications 2017 cited by 173

  15. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

    Authors: Bradley J. Monk, Mark F. Brady, Carol Aghajanian, Heather A. Lankes, Tina Rizack, Joseph W. Leach, J.M. Fowler, Robert V. Higgins, P. Hanjani, Mark A. Morgan, Robert P. Edwards, William H. Bradley, Tatjana Kolevska, Periklis Foukas, E. Swisher, Karen S. Anderson, Raphaël Gottardo, J.K. Bryan, Mona Newkirk, Kristi L. Manjarrez, Robert S. Mannel, Robert M. Hershberg, George Coukos - Annals of Oncology 2017 cited by 93

  16. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

    Authors: Benoît You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini F. Fleming, Robert L. Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David E. Cohn, Mahvish Muzaffar, David G. Mutch, Andrea E. Wahner Hendrickson, Lainie P. Martin, Olivier Colomban, Robert A. Burger - Journal of Clinical Oncology 2022 cited by 75

  17. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

    Authors: Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Krishnansu S. Tewari, Floor Backes, Robert S. Mannel, Gretchen Glaser, Cheryl L. Bailey, Stephen C. Rubin, John T. Soper, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Michael J. Birrer, Elizabeth M. Swisher - Clinical Cancer Research 2017 cited by 235

  18. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

    Authors: Joan L. Walker, Mark F. Brady, Lari Wenzel, Gini F. Fleming, Helen Huang, Paul DiSilvestro, Keiichi Fujiwara, David S. Alberts, Wenxin Zheng, Krishnansu S. Tewari, David E. Cohn, Matthew A. Powell, Linda Van Le, Susan A. Davidson, Heidi J. Gray, Peter G. Rose, Carol Aghajanian, Tashanna Myers, Angeles Alvarez Secord, Stephen C. Rubin, Robert S. Mannel - Journal of Clinical Oncology 2019 cited by 232

  19. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

    Authors: Carlos Bais, Barbara M. Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger, Wei Wei, Koen M. Marien, Mark Kockx, Amreen Husain, Michael J. Birrer, NRG Oncology/Gynecologic Oncology Group - JNCI Journal of the National Cancer Institute 2017 cited by 108

  20. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Authors: Marcus E. Randall, Virginia L. Filiaci, Hyman B. Muss, Nick M. Spirtos, Robert S. Mannel, Jeffrey Fowler, J.T. Thigpen, J Bénda - Journal of Clinical Oncology 2005 cited by 870

  21. Randomized Double-Blind Trial of Estrogen Replacement Therapy Versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group Study

    Authors: Richard R. Barakat, Brian N. Bundy, Nick M. Spirtos, Jeffrey G. Bell, Robert S. Mannel - Journal of Clinical Oncology 2006 cited by 230

  22. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

    Authors: Kate Oliver, William E. Brady, Michael J. Birrer, David M. Gershenson, Gini F. Fleming, Larry J. Copeland, Krishnansu S. Tewari, Peter A. Argenta, Robert S. Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John Farley - Gynecologic Oncology 2017 cited by 99

  23. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

    Authors: Angeles Alvarez Secord, Kirsten B. Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O’Malley, Heidi J. Gray, Jamie N. Bakkum‐Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon - Clinical Cancer Research 2020 cited by 57

  24. LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

    Authors: Ramez N. Eskander, Michael W. Sill, Austin Miller, Lucas R. Beffa, Richard G. Moore, Joanie Mayer Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, G. Canturia, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Erin Hinchcliff, Shashikant Lele, Matthew A. Powell, Carol Aghajanian - Annals of Oncology 2023 cited by 19